The Committee for Medicinal Products for Human Use (CHMP) decided that Avandamet’ s benefits are greater than its risks for the treatment of type 2 diabetes mellitus patients.
Inimravimite komitee jõudis otsusele, et Avandameti kasulikkus II tüüpi suhkurtõve ravis on suurem kui sellega kaasnevad riskid.